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Abstract: Positron emission tomography (PET) ligands targeting the translocator protein (TSPO)
represent promising tools to visualize neuroinflammation in multiple sclerosis (MS). Although it
is known that TSPO is expressed in the outer mitochondria membrane, its cellular localization in
the central nervous system under physiological and pathological conditions is not entirely clear.
The purpose of this study was to assess the feasibility of utilizing PET imaging with the TSPO
tracer, [18F]-GE180, to detect histopathological changes during experimental demyelination, and to
determine which cell types express TSPO. C57BL/6 mice were fed with cuprizone for up to 5 weeks
to induce demyelination. Groups of mice were investigated by [18F]-GE180 PET imaging at week
5. Recruitment of peripheral immune cells was triggered by combining cuprizone intoxication
with MOG35–55 immunization (i.e., Cup/EAE). Immunofluorescence double-labelling and transgene
mice were used to determine which cell types express TSPO. [18F]-GE180-PET reliably detected
the cuprizone-induced pathology in various white and grey matter regions, including the corpus
callosum, cortex, hippocampus, thalamus and caudoputamen. Cuprizone-induced demyelination
was paralleled by an increase in TSPO expression, glia activation and axonal injury. Most of the
microglia and around one-third of the astrocytes expressed TSPO. TSPO expression induction was
more severe in the white matter corpus callosum compared to the grey matter cortex. Although
mitochondria accumulate at sites of focal axonal injury, these mitochondria do not express TSPO.
In Cup/EAE mice, both microglia and recruited monocytes contribute to the TSPO expressing cell
populations. These findings support the notion that TSPO is a valuable marker for the in vivo
visualization and quantification of neuropathological changes in the MS brain. The pathological
substrate of an increase in TSPO-ligand binding might be diverse including microglia activation,
peripheral monocyte recruitment, or astrocytosis, but not axonal injury.
Keywords: multiple sclerosis; cuprizone; TSPO; PET; neurodegeneration
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1. Introduction
Multiple sclerosis (MS), an inflammatory disorder of the central nervous system (CNS),
is associated with the development of demyelinated plaques, oligodendrocyte destruction and axonal
degeneration. These pathological processes are paralleled by the activation of astrocytes and microglia,
as well as the recruitment of peripheral immune cells into the central nervous system (CNS) [1,2].
Notwithstanding the traditional focus on white matter tracts as the predominantly affected regions in
the CNS of MS patients, demyelination also occurs in various grey matter brain regions [3–5], including
the hippocampus [6], neocortex [7], thalamus [5], and caudoputamen [5,8]. MS can present in different
clinical courses. Relapsing-remitting MS (RRMS) is characterized by single attacks (also known as
relapses) with full or partial recovery. There is minimal to no disease progression during the periods
between two relapses. Secondary progressive MS (SPMS) is characterized by an initial RRMS disease
course, followed by gradual worsening with or without occasional relapses. During this progressive
disease course, progression occurs independent of the relapses. Primary progressive MS (PPMS) is
characterized by the progressive accumulation of disability from disease onset. During the RRMS
disease course, multifocal inflammatory lesions dominate the pathological process, whereas the
gradual accumulation of irreversible disability that characterizes progressive MS seems to result more
from diffuse immune mechanisms and neurodegeneration [1,9]. As a result, the currently approved
drugs for the treatment of RRMS have marginal or no efficacy in progressive MS without inflammatory
lesion activity. The development of effective therapies for progressive MS that prevent worsening,
reverse damage, and restore function are a major unmet medical need [9].
The pathogenic cascade(s) underlying neurodegeneration is incompletely understood. Recent
data suggest that CNS-resident microglia as well as infiltrating inflammatory monocytes play a key role
in neurodegeneration [10,11]. For example, microglia cells together with newly recruited blood-borne
macrophages orchestrate a new demyelination process by myelin phagocytosis [12]. Moreover,
microglial cells are considered to be the main antigen presenting cell population in the CNS and might
therefore play important roles during lymphocyte reactivation [13,14]. In the brains of MS patients,
microglial activation is not restricted to the focal inflammatory lesions but also diffusely present in
normal appearing white and gray matter areas. Therefore, diffuse microglia activation might be
responsible for the diffuse neurodegeneration seen in MS patients [15]. Furthermore, in preclinical MS
models acute axonal injury predominantly occurs in regions with pronounced microglia activation [16].
If microglia sense injury, they are rapidly activated and respond by the production of cytokines and
chemokines, increased phagocytosis, the release of reactive oxygen species as well as by antigen
presentation [17,18]. By these mechanisms, microglia can trigger the activation of neurotoxic pathways
leading to progressive neurodegeneration. Manipulation of microglia cell function might, therefore,
be a valuable strategy to ameliorate or even prevent neurodegeneration in MS patients, and in
consequence alleviate disease progression. However, formal proof that the (prolonged) presence of
activated microglia is indeed detrimental in MS remains to be established. Hence, a valid method to
measure microglia activation in MS patients is urgently needed.
One of the molecules that is highly expressed by activated microglia is the mitochondrial
translocator protein 18 kDa (TSPO), formerly known as the “peripheral benzodiazepine receptor” [19].
TSPO is a receptor that is part of a multimeric complex. This complex includes a voltage-dependent
anion channel and an adenine nucleotide carrier and locates to the outer mitochondrial membrane [20].
There, TSPO is believed to play crucial roles in cell physiology and development, as suggested by
its sequence conservation from bacteria to humans [21]. Although TSPO is believed to be important
for maintaining the mitochondrial membrane potential, this protein is also critically involved in
cholesterol transport, making it essential for steroidogenesis [22]. In addition, TSPO plays roles
in cellular proliferation, apoptosis and inflammation as well as in porphyrin transport and haem
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biosynthesis (see [23,24]) for excellent reviews]. In the CNS, TSPO is thought to be mainly expressed by
activated microglia cells, although various other cell types, including endothelial and smooth muscle
cells, astrocytes and ependymal cells, were shown to express TSPO [25]. In MS tissues and other
CNS disorders, microglia and macrophages are believed to represent the bulk of TSPO+ cells [25–27].
However, astrocytes have also been shown to upregulate TSPO expression during CNS injuries [26,28].
In fact, the relative contribution of astrocytes to the global binding of TSPO ligands has been, and still
is, a matter of debate [29].
Today, conventional MR imaging (MRI) techniques represent an important step during MS
diagnostics and clinical follow-up. It is sensitive in demonstrating focal inflammatory lesions and,
to a certain extent, diffuse brain atrophy. However, the widespread diffuse pathology within the
normal appearing white matter as well as grey matter pathology, which is often related to microglial
activation and neurodegeneration, cannot be reliably detected using conventional MRI [30]. Positron
emission tomography (PET) is a sensitive method for visualizing MS-related processes at the molecular
level, and is a useful tool to visualize neuroinflammation and the activation of microglia [31]. In contrast
to other imaging modalities, PET can visualize cell metabolism in real time, and physiological
parameters can be quantified in active disease processes. TSPO is the most widely used target in PET
imaging of neuroinflammation. The first successful and now most frequently used TSPO-radioligand
is (11C) PK11195 [32]. However, (11C) PK11195 has several disadvantages, including limited brain
entrance, a poor signal-to-noise ratio and labelling with the impractically rapid decaying isotope,
(11C) [31]. This led to the development of a wide range of second- and third-generation TSPO
radioligands, including (18F)-GE180 [33] which indicated good performance in MS patients [34,35].
The cellular source of TSPO expression, and hence TSPO-ligand binding in the CNS of MS
patients is not entirely clear. While most studies suggest that TSPO is predominatly expressed by
activated microglia cells and in consequence an increase in TSPO ligand binding is interpretated
as microglia activation [36–40], various other cell types have been shown to express TSPO as well,
including astrocytes [41,42]. The aim of this study was, therefore, to establish the applicability
of the third-generation TSPO ligand, (18F)-GE180, to (semi-)quantify glia cell activation and
neuroinflammation in a MS mouse model, and to directly correlate ligand binding with TSPO
expression. Furthermore, we readdressed which cell types express TSPO after experimental
demyelination with a focus on astrocytes, microglia cells and sites of acute axonal injury.
2. Material and Methods
2.1. Animals and Experimental Groups
All in vivo experiments were performed as published previously with minor modifications [43–45].
Eight-week-old C57BL/6 female mice (19–20 g) were purchased from Janvier Labs, Le Genest-Saint-Isle,
France. The mice were allowed to accommodate to the environment for at least 1 week prior to
the beginning of the experiment. The hGFAP/EGFP transgenic mice [46] were used to visualize
entire astrocyte cell bodies and processes. The CX3CR1+/eGFP/CCR2+/RFP-mice with RFP-expressing
monocyte-derived macrophages and eGFP-expressing microglia [47] were used to analyze whether TSPO
is expressed in microglia and/ or monocytes. Microbiological monitoring was performed according to
the Federation of European Laboratory Animal Science Associations recommendations. A maximum
of five animals were housed per cage (cage area 435 cm2). The animals were kept at a 13 h light/11 h
dark cycle, with a controlled temperature of 22 ± 2 ◦C and 50 ± 10% humidity, with access to food and
water ad libitum. It was assured that no light was used during the night cycle period. Nestlets were
used for environmental enrichment. The housing conditions for the PET scanned mice were slightly
different, e.g., 12 h light/ 12 h dark cycle and six animals per cage. All experiments were formally
approved by the Regierung Oberbayern (reference number 55.2-154-2532-73-15). The mice were randomly
assigned to the following experimental groups: (A) control (co), the animals were provided a diet of
standard rodent chow for the entire duration of the study; (B) cuprizone, the animals were intoxicated
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with a diet containing 0.25% cuprizone (bis(cyclohexanone)oxaldihydrazone; Sigma-Aldrich, Taufkirchen,
Germany) mixed into ground standard rodent chow for one week (1 wk cup), three weeks (3 wks cup),
or five weeks (5 wks cup); (C) Cup/EAE, the mice were intoxicated with the cuprizone diet for the
first three weeks, and were then immunized with MOG35–55 at the beginning of week six as published
previously [43,44]; (D) EAE, the animals received the standard rodent chow for the duration of the study
and were immunized with MOG35–55 at the beginning of week six.
2.2. EAE and Disease Scoring
EAE scoring was daily performed as published previously [43]. To induce the formation of
encephalitogenic T cells, the mice were immunized (s.c.) with an emulsion of MOG35–55 peptide dissolved
in complete Freund’s adjuvant followed by injections of pertussis toxin in PBS (i.p.) on the day of and the
day after immunization (Hooke Laboratories, Inc., Lawrence, USA). The disease severity was scored as
follows: A score of 1 was assigned if the entire tail droped over the finger of the observer when the mouse
was picked up by the base of the tail; a score of 2 was assigned when the legs of the mice were not spread
apart but held close together when the mouse was picked up by the base of the tail, or when mice exhibited
a clearly apparent wobbly gait; a score of 3 was assigned when the tail was limp and the mice showed
complete paralysis of hind legs (a score of 3.5 is given if the mouse is unable to raise itself when placed on
its side); a score of 4 was assigned if the tail was limp and the mice showed complete hind leg and partial
front leg paralysis, and the mouse was minimally moving around the cage but appears alert and feeding.
A score of 4 was not attained by any of the mice in our study.
2.3. Positron Emission Tomography (PET)—Imaging
All rodent PET procedures followed an established standardized protocol for radiochemistry,
acquisition and post-processing [48,49]. In brief, [18F]-GE180 TSPO-PET (10.6 ± 2.1 MBq) with
an emission window of 60–90 min p.i. was used to measure cerebral microglial activity by a Siemens
Inveon DPET (Siemens, Knoxville, Tennessee). All analyses were performed using PMOD (V3.5,
PMOD technologies, Basel, Switzerland). Normalization of the injected activity was performed
by the previously validated myocardium correction method [50]. TSPO-PET values, derived from
a predefined VOI (volume of interest) set (medial corpus callosum (2.2 mm3), the lateral corpus
callosum (2.9 mm3), caudoputamen (4.4 mm3), thalamus (4.4 mm3), hippocampus (4.4 mm3), and cortex
(6.7 mm3)) were extracted and compared between groups (co versus 5 wks cup) by a Mann–Whitney
test. A visual comparison was performed by the calculation of a standardized Z-score difference map
for each cerebral voxel for control versus 5 wks cup. To this end, the average and standard deviation
maps were generated for the groups of control and 5 wks cup, and the difference between the control
and 5 wks cup average maps was scaled by the standard deviation map of control.
2.4. Gene Expression Studies
The gene expression levels were semi-quantified by real-time reverse transcription-PCR
([qRT-PCR] Bio-Rad, Munich, Germany), using SensiMix Plus SYBR and fluorescein (Quantace,
Bioline, Luckenwalde, Germany) with a standardized protocol as described previously by our
group [51]. The primer sequences and individual annealing temperatures are shown in Table 1.
Relative quantification was performed using the ∆∆Ct method. The β-actin expression levels were
used as the reference. Gel electrophoresis and melting curves of the PCR products were routinely
performed to determine the specificity of the PCR reactions (data not shown). To exclude contamination
of the reagents with either RNA or DNA, appropriate negative controls were performed.
Table 1. List of primers used in this study (AT—annealing temperature; bp—base pair length).
Sense Antisense Bp AT
TSPO1 GCCTACTTTGTACGTGGCGAG CCTCCCAGCTCTTTCCAGAC 152 60
β-Actin 1 GTACCACCATGTACCCAGGC AACGCAGCTCAGTAACAGTCC 247 60
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2.5. Tissue Preparation
For the histological and immunohistochemical studies, the mice were anaesthetized with ketamine
(100 mg·kg−1 i.p.) and xylazine (10 mg·kg−1 i.p.), and then transcardially perfused with ice-cold PBS
followed by a 3.7% formaldehyde solution (pH 7.4). The brains were postfixed in a 3.7% formaldehyde
solution overnight, dissected, embedded in paraffin, and then the coronal sections (5 µm) were
prepared. For the gene expression studies, after transcardial PBS perfusion, the tissues were manually
dissected and cut with a vibratom into 400 µm slices. The hippocampus, corpus callosum and cortex
tissues were dissected, and the samples were stored at 0 ◦C in homogenization tubes filled with 1 mL
peqGold TriFast (Peqlab Biotechnologie GmbH, Erlangen, Germany) until further processing.
2.6. Immunohistochemistry
Immunohistochemistry was performed as previously published by our group [43,45]. In brief,
the antigens were unmasked with heating in either Tris/EDTA (pH 9.0) or citrate (pH 6.0) buffer
if appropriate. After washing in PBS, the sections were blocked in blocking solution (serum of the
species in which the secondary antibody was produced) for 1 h. Then, the sections were incubated
overnight (4 ◦C) with the primary antibodies diluted in blocking solution. The primary antibodies
used in this study are given in Table 2. The next day, the slides were treated with 0.3% hydrogen
peroxide in PBS for 30 min and then incubated with biotinylated secondary antibodies for 1 h followed
by peroxidase-coupled avidin-biotin complex (ABC kit; Vector Laboratories, Peterborough, UK).
The secondary antibodies used in this study are listed in Table 3. The sections were finally exposed
to 3,3’-diaminobenzidine (DAKO, Santa Clara, CA, USA) as a peroxidase substrate as published
previously [16]. The negative control sections, without primary antibodies or with isotype antibodies,
were processed in parallel to ensure specificity of the staining. The stained and processed sections were
digitalized using a Nikon ECLIPSE 50i microscope (Nikon, Nikon Instruments, Düsseldorf, Germany)
equipped with a DS-2Mv camera. The open source program, ImageJ (NIH, Bethesda, MD, USA),
was used to determine the relative area stained by the anti-TSPO antibodies.
Table 2. List of the antibodies used in this study.
Antigen Species Dilution HIER Method PurchaseNumber RRID Company
Single stains
PLP Mouse 1:5,000 None MCA839G AB_2237198
Bio-Rad
Laboratories,
Inc., Germany
TSPO/PBR Goat 1:100 Tris/EDTA ab118913 AB_10898989 Abcam, UK
Iba1 Rabbit 1:5,000 Tris/EDTA 019–19741 AB_839504 Wako, USA
GFAP Chicken 1:5,000 Citrate ab4674 AB_304558 Abcam, UK
Double stains
TSPO/PBR Goat 1:100 Tris/EDTA ab118913 AB_10898989 Abcam, UK
GFAP Mouse 1:400 Tris/EDTA G3893 AB_477010 Sigma-Aldrich,USA
Iba1 Rabbit 1:2,500 Tris/EDTA 019-19741 AB_839504 Wako, USA
APP Mouse 1:1,000 Tris/EDTA MAB348 AB_94882 Millipore,Germany
COXIV Rabbit 1:500 Tris/EDTA ab16056 AB_443304 Abcam, UK
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Table 3. List of the secondary antibodies used in this study.
Order Number RRID Supplier
Rabbit anti-goat IgG BA-5000 AB_2336126 Vector Laboratories, Burlingame, USA
Goat anti-rabbit IgG BA-1000 AB_2313606 Vector Laboratories, Burlingame, USA
Goat anti-mouse IgG BA-9200 AB_2336171 Vector Laboratories, Burlingame, USA
Goat anti-chicken IgG BA-9010 AB_2336114 Vector Laboratories, Burlingame, USA
Cy3 donkey anti-goat IgG 705-165-147 AB_2307351 Jackson ImmunoResearch Labs
Alexa Fluor 488 donkey anti-rabbit IgG A21206 AB_2535792 Invitrogen, USA
Alexa Fluor 488 donkey anti-mouse IgG A21202 AB_141607 Invitrogen, USA
2.7. Immunofluorescence Labeling
For immunofluorescence stains, the sections were rehydrated, unmasked, and blocked in the
serum of the species in which the secondary antibodies were raised. The sections were incubated
overnight (at 4 ◦C) with the indicated combination of primary antibodies diluted in blocking
solution. The primary antibodies used in this study are listed in Table 2. For double-labelling
experiments, the anti-TSPO antibodies were either combined with anti-IBA1 for the detection of
microglia/macrophages, or anti-GFAP for the detection of astrocytes. Acute axonal injury was
visualized with anti-APP antibodies. After extensive washing, the sections were incubated with
a combination of fluorescent secondary antibodies (Table 3). For the staining of cell nuclei, the sections
were then incubated with Hoechst 33258 (bisBenzimide H 33258 Sigma Aldrich, Steinheim, Germany;
1:10,000) diluted in PBS. In parallel, the negative controls were performed by first incubating
sections with the primary antibodies and subsequently incubating these sections with the “wrong”
secondary antibodies to exclude unspecific binding of the fluorescent secondary antibodies to primary
antibodies [52]. By incubating the sections with each of the fluorescent secondary antibodies alone,
unspecific secondary antibody binding to the tissue itself was excluded. The stained and processed
sections were documented using an Olympus BX41-Wi fluorescence microscope station (Olympus,
Hamburg, Germany). The software, Stereo Investigator (MBF Bioscience, Williston, ND, USA),
was used to determine the number of single and double-positive cells/spheroids.
2.8. Ultrastructural Analysis via Serial Block-Face Scanning Electron Microscopy
Myelinated and demyelinated corpora callosa (i.e., 3 wks cuprizone) were analyzed by 3D EM as
published by Ohno and colleagues [53]. To this end, the mice were perfused via the left ventricle with
2.5% (wt/vol) glutaraldehyde and 4% paraformaldehyde. The brains were subsequently removed,
stained with heavy metals, and embedded in resin. 3D-electron microscopy (Serial block-face scanning
EM) was performed by using a SigmaVP scanning electron microscope (Carl Zeiss) equipped with
a 3View in-chamber ultramicrotome system (Gatan). Serial image sequences were generated at
80 nm-nm steps, providing 204.54 µm × 61.36 µm-wide image stacks at a resolution of 0.001 µm per
pixel. The images were processed and measured with the open source program, Reconstruct (BU,
Boston, MA, USA). The focus of this analysis was to detect mitochondria within axonal swellings.
2.9. Statistical Analysis
All data are given as arithmetic means ± SEMs. A p-value of <0.05 was considered to be
statistically significant. Statistical analyses were performed using Prism 5 (GraphPad Software Inc.,
San Diego, CA, USA). Applied statistical tests are given in the respective figure legends.
3. Results
3.1. Cuprizone Intoxication Induces Reproducible Demyelination and Glia Activation
First, we analyzed the spatial distribution of cuprizone-induced demyelination and glia activation
after a 5-week cuprizone intoxication protocol. Compared to the control animals, severe loss of anti-PLP
staining intensity was evident in several brain regions, including the corpus callosum, grey matter cortex
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and caudoputamen (see Figure 1A). At the level of the anterior commissure, demyelination of the corpus
callosum was prominent at the lateral parts, whereas, at the level of the rostral hippocampus, the medial
corpus callosum was most severely demyelinated. Moreover, moderate but consistent demyelination
was observed in the hippocampus. To analyze the extent of microglia and astrocyte activation, anti-IBA1
and anti-GFAP immunohistochemical stains were performed, respectively. As shown in Figure 1B, C,
demyelination was paralleled by severe microgliosis and astrocytosis. Anti-IBA1 and anti-GFAP staining
intensity was most severe within the demyelinated corpus callosum, less so in the affected grey matter
cortex and hippocampus. Within the caudoputamen, microgliosis and astrocytosis were severe within the
demyelinated striosomes, and moderate in the matrix region.
Figure 1. Cuprizone-intoxication induces multifocal demyelination and reactive glia activation.
(A) The myelination of different brain areas, determined by anti-PLP staining. The upper row shows
representative pictures of the control (n = 4), and the lower row shows representative pictures of the
cuprizone-intoxicated animals (5 weeks; n = 4). (B) Cuprizone-induced demyelination is paralleled by
microglia activation (shown with IBA1 immunoreactivity; n = 4), and (C) astrocyte activation (shown
with GFAP immunoreactivity; n = 4). medCC (medial part of the corpus callosum); latCC (lateral
part of the corpus callosum); Cx (cortex); CP (caudoputamen); HC (hippocampus). Differences were
determined using Mann–Whitney tests. * p < 0.05, ** p < 0.01, and *** p < 0.001.
3.2. TSPO Expression and (18F)-GE180 Uptake Correlate with the Degree of Demyelination and Glial
Cell Activation
Different cell types have been discussed to induce TSPO expression in response to brain injuries,
including microglia and astrocytes. During inflammatory demyelination, a third cell type might
contribute to the global brain TSPO load, namely, recruited monocytes. In a first step, we applied
the reductionistic cuprizone demyelination model where demyelination occurs despite the presence
of an intact blood–brain barrier, and, in consequence, the absence of peripheral monocytes and
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lymphocytes [54]. In that model, we performed µPET analyses in control and 5-week cuprizone-treated
animals to quantify uptake of the novel TSPO ligand, (18F)-GE180 [55], and compared ligand uptake
to histopathological changes.
In line with previous results [41,56], we found a region-dependent increase of [18F]-GE180 uptake
in cuprizone-treated mice (Figure 2A). A visual interpretation of the TSPO µPET scans indicated
increased tracer uptake, particularly in the corpus callosum, caudoputamen, thalamus and cortex
regions (Figure 2B). Statistical comparison between the control and cuprizone-intoxicated mice showed
significant higher tracer uptake in the medial corpus callosum (∆36 ± 4%, p < 0.001), the lateral corpus
callosum (∆58 ± 5%, p < 0.001), the caudoputamen (∆65 ± 5%, p < 0.001), the thalamus (∆47 ± 5%,
p < 0.001), the hippocampus (∆46 ± 5%, p < 0.001), and the cortex (∆54 ± 5%, p < 0.001).
Figure 2. In vivo imaging demonstrates an increase in [18F]-GE180 uptake after cuprizone-intoxication.
(A) The definition of VOIs (volumes of interest), demonstrated in a mouse brain MRI atlas in the
coronal slides: medial corpus callosum (2.2 mm3), lateral corpus callosum (2.9 mm3), caudoputamen
(4.4 mm3), thalamus (4.4 mm3), hippocampus (4.4 mm3), and cortex (6.7 mm3). (B) The quantification
of radioligand uptake in the control animals (n = 4) and after a 5-week cuprizone intoxication period
(n = 4). (C) Schematic illustration of the measured areas and cumulative heat map illustrating
radioligand uptake in cuprizone-treated mice. The color codes demonstrate the standardized
radioligand uptake levels relative to the controls (Z-scores; left column), and the normalized uptake
in cuprizone-treated (middle column) and control (right column) mice. Cx (cortex); CC (corpus
callosum); HC (hippocampus); Th (thalamus); CP (caudoputamen). Differences were determined using
Mann–Whitney tests. * p < 0.05, ** p < 0.01, and *** p < 0.001.
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In order to relate the observed increased tracer uptake in vivo to the histological changes,
we analyzed TSPO reactivity in the different brain regions. In control animals, the anti-TSPO
staining intensity of the brain parenchyma was generally weak. Consistent with the reported
mitochondrial localization of the TSPO protein, the quality of the staining was punctate [25]. Due to
the punctate nature of the cell processes, complete cell shapes could not easily be deciphered.
In line with previous observations, the positive immunohistochemical staining for TSPO was
cytoplasmatic [57]. Occasionally, positively-stained process-bearing cells were identifiable as glial cells
(arrow in Figure 3A), resembling either microglia or astrocytes. Furthermore, TSPO-expressing cells
with multiple processes that appeared to be oligodendrocyte progenitor cells were found in the cortex
(see Figure 3B). No staining was observed if the primary antibody was omitted (not shown). Additional
cells/areas in which TSPO immunoreactivity was observed in the control brains included cekks in
the subpial glia (probably both astrocytes and microglia; arrows in Figure 3C), meninges, ependymal
cells (arrows in Figure 3D), as well as cells in the choroid plexus (vessels, macrophages, and choroid
plexus epithelial cells; see Figure 3E). TSPO+ cells, resembling oligodendrocytes, were also observed
(arrows in Figure 3F). Again, the staining pattern in these cells tends to be punctate or granular.
Furthermore, neuronal cell bodies were labelled with punctuate spots (not shown). The brains of
cuprizone-intoxicated mice displayed staining in compartments observed in the control cases (such as
in the meninges, neurons and ependymal cells), but also showed markedly enhanced staining in the
parenchyma, particularly in regions of demyelination such as the corpus callosum (see Figure 3G–I).
In such areas of intense demyelination, ramified glial cells had enhanced TSPO positivity, most of
which were clearly identifiable as activated microglia (see Figure 3J/K). TSPO+ hypertrophic astrocytes
were also present in the brains of cuprizone-intoxicated mice, identified based on their morphology
(arrows in Figure 3L).
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Figure 3. Expression of TSPO in cuprizone-intoxicated mice. The representative results of the
anti-TSPO immunohistochemistry demonstrating the expression of TSPO in perivascular astrocytes
(arrow in A), oligodendrocyte progenitor cells (B), glia cells beneath the pial surface of the cortex
(C), ependymal cells lining the lateral ventricles (D), choroid plexus cells (E) and interfascicular
oligodendrocytes in the corpus callosum (arrows in F). (G) Schematic illustration of the investigated
regions. (H–K) The representative results of the anti-TSPO immunohistochemistry in the control
or cuprizone-intoxicated mice. (L) A high-power view of an anti-TSPO+ astrocyte (arrows) in the
corpus callosum of cuprizone-intoxicated mice. (M) The densitometric quantification of the anti-TSPO
staining intensity in different brain areas. (N) The quantification of anti-TSPO+ cell densities in the
somatosensory cortex of control and 5-week cuprizone-intoxicated mice, with representative pictures
shown in (J) and (K). mCC (medial part of the corpus callosum); Cx (cortex); CP (choroid plexus).
Differences between the groups were statistically tested using two-tailed t-test. Welsh correction was
applied for the medial corpus callosum. * p < 0.05, ** p < 0.01, and *** p < 0.001.
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The densitometrical quantification of TSPO staining intensity revealed significantly higher
expression levels in the medial (∆153 ± 15%, p < 0.001) and lateral (∆151 ± 11%, p < 0.001) corpus
callosum, caudoputamen (∆82 ± 15%, p < 0.001), thalamus (∆35 ± 6%, p < 0.001) and hippocampus
(∆128 ± 23%, p < 0.05), but not in the cortex region. Due to the discrepancy of cortical TSPO expression
based on immunohistochemical evaluation, and in vivo µPET analyses, we additionally quantified the
densities of TSPO+ cells in the cortex of the control and cuprizone-intoxicated mice, which is a more
sensitive method to detect subtle expression differences. As shown in Figure 3N, higher densities of
TSPO+ cells were found in the cortex of the cuprizone-intoxicated mice compared to the control mice.
To verify induced TSPO expression in the cuprizone model, we quantified Tspo mRNA expression
by rt RT-PCR in the corpus callosum and cortex after 1, 3 and 5 weeks of cuprizone intoxication.
As demonstrated in Figure 4, higher Tspo expression levels were found in both the white matter corpus
callosum and grey matter cortex region. Additionally, the extent of Tspo mRNA expression induction
was greater in the corpus callosum compared to the cortex.
Figure 4. Expression levels of Tspo mRNA during the course of cuprizone-induced demyelination.
Tspo mRNA levels in the control animals (n = 5) and the animals intoxicated with cuprizone for one
(n = 5), three (n = 5) or five (n = 5) weeks. Differences between the groups were statistically tested
using one-way ANOVA with the obtained p-values corrected for multiple testing using the Dunnett’s
post-hoc test; * p ≤ 0.05, ** p ≤ 0.05, *** p ≤ 0.001.
3.3. TSPO Mainly Co-Localizes with Microglia
As stated above, based on their morphology, TSPO+ cells were identifiable as glial cells,
resembling either microglia or astrocytes. Furthermore, it has been suggested that both activated
astrocytes and microglia are responsible for the enhanced TSPO-ligand binding in brain areas
undergoing cuprizone-induced demyelination [41,58]. To test for this, IBA1/TSPO and GFAP/TSPO
double-labelling experiments were performed, and absolute glial cell densities as well as numbers of
glia cells expressing the respective glia cell marker protein and TSPO (IBA1+/TSPO+ or GFAP+/TSPO+)
was evaluated in the white matter corpus callosum and grey matter cortex after 1, 3 and 5 weeks of
cuprizone intoxication. As shown in Figure 5, the densities of the IBA1+ cells gradually increased in
the corpus callosum during the course of cuprizone-induced demyelination. At week 5, the mean
density of the IBA1+ cells in the medial corpus callosum was 687.5 ± 300.75 cells/mm2. Most of the
IBA1+ cells also expressed TSPO (665 ± 291.82 cells/mm2; ~97%). In line with previous results [59],
the extent of microgliosis was less severe and delayed in the cortex (control: 137.5 ± 35.35 cells/mm2
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versus 5 weeks of cuprizone: 197.5 ± 80.325 cells/mm2). Comparable to what we found in the corpus
callosum, most of the IBA1+ cells in the cortex expressed TSPO at week 5 (192.5 ± 84.2 cells/mm2;
~97%). The situation for GFAP expressing cells was different. Although the densities of the GFAP+
cells gradually increased in the corpus callosum and cortex during the course of cuprizone-induced
demyelination, a significant proportion of the GFAP+ cells were TSPO-negative in the control and
cuprizone-exposed mice (see Figure 6). At week 5, ~31% of GFAP+ astrocytes co-expressed TSPO in
the white matter corpus callosum, whereas ~23% of GFAP+ astrocytes co-expressed TSPO in the grey
matter cortex. To verify TSPO expression in the astrocytes, the brain slides from the cuprizone-treated
hGFAP-eGFP-mice were processed for anti-TSPO immunoflourescence staining. These mice express
eGFP not only in proximal processes, but also in the fine distal processes of astrocytes [46]. In line with
our results that were obtained by fluorescence-double-labelling, the anti-TSPO signal could clearly be
localized to the astrocyte cell bodies (see Figure 6C).
Figure 5. Co-localization of TSPO with the microglia/monocyte marker, IBA1. (A) The representative
images of IBA1 (green) and TSPO (red) immunofluorescence double stains in the control and 5-week
cuprizone-intoxicated mice (left: corpus callosum; right: cortex). The white boxes highlight cells
which are shown on the right-hand side at higher magnification. (B) The quantification of entire IBA1+
cell densities (white columns) and IBA1+/TSPO+ double positive cell densities (grey columns) in the
control animals (n = 4) and the animals intoxicated with cuprizone for one (n = 5), three (n = 5) or five
(n = 5) weeks.
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Figure 6. Co-localization of TSPO with the astrocyte marker protein, GFAP (A). The representative
images of GFAP (green) and TSPO (red) immunofluorescence double stains in the control and 5-week
cuprizone-intoxicated mice (left: corpus callosum; right: cortex). The white boxes highlight cells
which are shown on the right-hand side at higher magnification. (B) The quantification of the entire
GFAP+ cell densities (white columns) and GFAP+/TSPO+ double positive cell densities (grey columns)
in the control animals (n = 4) and the animals intoxicated with cuprizone for one (n = 5), three
(n = 5) or five (n = 5) weeks. (C) The representative images demonstrating expression of TSPO (red) in
eGFP-expressing astrocytes (green).
3.4. TSPO Is Not Expressed in the Mitochondria of Injured Axons
Different groups reported an increase in mitochondrial content (through an increase in size and
number) within demyelinated axons in MS as well as following experimental demyelination [53,60,61].
Therefore, increased (18F)-GE180 binding levels might principally also be due to an increase in the
axonal mitochondrial load. To test for this possibility, we first used 3D-electron microscopy to observe
the accumulation of mitochondria in the corpus callosum of cuprizone-exposed mice. As expected,
numerous mitochondria were found in astrocytes (arrowheads in Figure 7A) and myelin-laden
microglia cells (arrowheads in Figure 7B). Some mitochondria were also present in normal-appearing,
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myelinated axons (arrowheads in Figure 7C). Additionally, pronounced mitochondrial accumulation
was frequently found at sites of axonal swelling (arrowheads in Figure 7D). 3D reconstruction of serial
blockface scanning 3D EM images revealed that in many cases, axonal mitochondrial density was high
at the close vicinity of an axonal swelling, but continuously declined with increasing distance to the
swelling (data not shown).
Figure 7. Accumulation of mitochondria in the damaged axons. The representative electron
microscopic images demonstrating mitochondria (arrowheads) in the astrocytes (A), phagocytosing
microglia (B), myelinated axons (C), or axonal swellings (D). The mice were intoxicated with
cuprizone for three weeks (n = 4). The arrowheads highlight mitochondria. (E) 3D reconstruction of
an axonal swelling. The mitochondria are highlighted by different colors. (F) The representative
image of APP (green) and COXIV (red) immunofluorescence double stains in the 5-week
cuprizone-intoxicated mice. The arrowhead highlights a COXIV+ single-positive, and the arrow
highlights a COXIV+/APP+ double-positive spheroid. (G) The representative image of APP (green)
and TSPO (red) immunofluorescence double stains in the 5-week cuprizone-intoxicated mice. The white
box highlights a region which is shown in (H), at higher magnification. (I) The percentage of microglia
(IBA1+), astrocytes (GFAP+) or axonal spheroids (APP+) co-expressing TSPO.
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To verify the ultrastructural data, the presence of mitochondria in axonal spheroids was
additionally visualized by APP/COXIV double-labelling experiments. As demonstrated in Figure 7F,
most of the APP+ spheroids contained COXIV+ mitochondrial profiles. Next, we looked for the
co-labelling of APP+ axonal spheroids with TSPO. Surprisingly, almost no TSPO+/APP+ spheroids
were found in the corpus callosum of cuprizone-treated mice (Figure 7I). In particular, ~97% of IBA1+
microglia cells, ~31% of GFAP+ astrocytes, but just ~3% of APP+ axonal spheroids co-expressed TSPO,
ruling out that increased [18F]-GE180 binding is due to mitochondrial accumulation within axons.
3.5. TSPO Is Expressed by Both Microglia and Monocytes in Inflammatory Lesions
The results from most studies suggest that cuprizone-induced pathology is characterized by
intense microglia accumulation [62], whereas peripheral immune cells have negligible significance for
cuprizone-induced demyelination. This reductionist model therefore does not allow the study of TSPO
expression of invading monocytes under demyelinating conditions. As recently published by our
group [43,44], the combination of cuprizone intoxication and MOG35-55 immunization (i.e., Cup/EAE)
results in significant peripheral immune cell recruitment. We took advantage of this model to
investigate the expression of TSPO in peripheral immune cells (see Figure 8A for the experimental
setup). MOG-EAE and Cup/EAE mice showed clinical signs of disease progression beginning
∼11 days after immunization, with the Cup/EAE-treated mice reaching slightly higher cumulative
(9.38 ± 1.14 versus 7.75 ± 1.05) and maximum (3.0 ± 0.2 versus 2.5 ± 0.35) disease scores than
MOG-EAE-treated mice (see Figure 8B). In line with our results described above, a significant increase
in anti-TSPO staining intensity was observed in the corpus callosum of only cuprizone-treated mice
(Figure 8D). In MOG-EAE mice, no significant increase in anti-TSPO staining intensity could be
observed in the corpus callosum (Figure 8E). However, in some cases, perivascular foci were in direct
vicinity of the third ventricle, and these foci showed pronounced TSPO immunoreactivity (Figure 8F).
In Cup/EAE mice, the TSPO staining intensity was pronounced in the cuprizone vulnerable regions,
such as the corpus callosum (Figure 8G). A particularly high TSPO staining intensity was observed
around perivascular inflammatory lesions (Figure 8H,I). To determine whether microglia or recruited
monocytes express TSPO in the Cup/EAE model, we utilized transgenic (CX3CR1+/eGFP/CCR2+/RFP)
mice with RFP-expressing monocyte-derived macrophages and eGFP-expressing microglia [47].
As shown in Figure 8J,K, the TSPO signal clearly co-localized to both, eGFP-expressing microglia
(arrow) and RFP-expressing monocyte-derived macrophages (arrowhead).
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Figure 8. Expression of TSPO in Cup/EAE mice (A). Schematic depicting the experimental
setup. The periods of normal chow diet are highlighted in blue. The periods of cuprizone
intoxication are highlighted in green, and the time point of MOG35–55 immunization with subsequent
active EAE development are highlighted in orange. (B) The clinical scores for MOG-EAE and
Cup/EAE treated mice with the time of onset, cumulative disease score and maximum disease
score (n = 4). The representative images of anti-TSPO immunohistochemistry in the controls (C),
cuprizone-intoxicated (D), MOG-EAE (E,F), and Cup/EAE (G–I) mice. The perivascular lesion,
highlighted in (H) by the black box, is shown in (I) at higher magnification. (J,K) The representative
images of the corpus callosum from cuprizone-treated mice, showing microglia (green), infiltrating
monocytes (red) and TSPO (blue). The arrow indicates TSPO expression in microglia cells, and the
arrowhead indicates TSPO expression in invaded monocytes.
4. Discussion
The present study demonstrates the temporal, regional and cellular patterns of TSPO expression
during the progression of cuprizone-induced demyelination in the mouse brain. Furthermore,
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this study indicates a very good applicability for monitoring neuroinflammatory processes using
the third-generation TSPO radioligand, (18F)-GE180. To the best of our knowledge, this is the first
study investigating cuprizone-intoxicated mice using (18F)-GE180 PET with the aim of quantifying
the uptake/binding in various anatomical brain regions, and correlating ligand uptake with
TSPO expression.
During the last two decades, the prototypic TSPO radioligand in use has been (11C)-PK11195,
with the first human brain studies conducted in patients with Rasmussen’s encephalitis [63],
with glioma [64], and in healthy controls and MS patients [32]. Using (11C)-PK11195 results in increased
binding in MS lesions, as demonstrated by postmortem studies and in vivo PET [29,65]. Although
(11C)-PK11195 showed promise as a biomarker in MS [66], newer TSPO-selective radioligands might
be superior to (11C)-PK11195 based on their higher brain uptake and more specific binding [67]. In this
study, we were able to demonstrate that cuprizone-induced demyelination is paralleled by an increase
in TSPO radioligand (18F)-GE180 uptake. Comparably, increased uptake of different TSPO ligands,
namely, [3H]-(R)-PK11195 [58,68], (123I)-CLINDE [41], and (125I)iodo-DPA-713 [56], has been shown
in the cuprizone model. It was suggested that, in the cuprizone model, the observed increase in
[3H]-R-PK11195 binding is a result of an increase in the apparent number of binding sites rather
than a change in receptor binding affinity [58]. In line with this assumption, we found higher TSPO
expression on the protein (Figure 3) and mRNA (Figure 4) level.
The cellular source of TSPO expression in the cuprizone model is not entirely clear. Mattner and
colleagues concluded, based on immunflourescence double-labelling experiments, that one of the
main sources of TSPO expression in the demyelinated corpus callosum is activated astrocytes. In these
studies, virtually all the GFAP-positive astrocytes as well expressed TSPO [41]. Chen and colleagues
performed GFAP or Mac-1 immunohistochemistry combined with (3H)-(R)-PK11195 autoradiography
and found co-localization of (3H)-(R)-PK11195 binding with both GFAP-expressing astrocytes and
Mac-1-expressing microglia [58]. In the current study, we quantified microglia (anti-IBA1) and astrocyte
(anti-GFAP) densities and determined the percentage of these cells expressing TSPO. As shown in
Figures 5 and 6, most of the IBA1+ cells co-expressed TSPO, whereas just about 30% of the GFAP+
cells co-expressed TSPO. Of note, the mapping of cellular expression of proteins in tissue subjected
to cuprizone-induced demyelination is not straightforward. After a 5-week cuprizone intoxication
protocol, the midline of the corpus callosum is hypercellular, making it difficult to delineate the border
of single cells. Furthermore, GFAP is not always expressed within the entire astrocyte cell body but
frequently spares one part of its perinuclear compartment. This anti-GFAP staining pattern causes
problems in delineating the exact border of a single astrocyte and, therefore, does not always allow to
decide whether a certain protein is expressed within an astrocyte or not. Additionally, the staining
efficacy of different antibodies or staining protocols might result in more or less co-localization signals.
To further verify that astrocytes express TSPO in the cuprizone model, we processed brain sections
of hGFAP-eGFP-mice for anti-TSPO immunoflourescence staining. These mice express eGFP not
only in the cell body and proximal processes, but also in the fine distal processes of astrocytes [46].
Furthermore, these mice express eGFP not in all but just a minority of astrocytes. This makes the
delineation of single astrocytes easy even in regions with high astrocyte density. As demonstrated in
Figure 6C, TSPO expression clearly co-localized to the eGFP signal. In summary, our data provide
unequivocal evidence that both activated astrocytes and microglia were responsible for the enhanced
[18F]-GE180 binding to TSPO in brain areas undergoing demyelination. Moreover, the bulk of TSPO
reactivity in the cuprizone model can be attributed to microglia. Notably, histological and imaging
findings in different types of MS lesions indicate that activated microglia are inflammatory modulators,
including inactive chronic and cortical lesions, as well as in normal appearing white and grey matter
areas [7]. Consequently, imaging microglial activation by PET using radiolabeled TSPO ligands should
provide a sensitive marker for neuroinflammatory processes.
High TSPO expression has been demonstrated in various macrophage populations such as
in synovial macrophages [69], myocardial macrophages [70], or macrophages of atherosclerotic
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plaques [71]. To determine whether recruited monocytes, in addition to microglia, express TSPO,
we combined the toxin-induced demyelination model cuprizone with the autoimmune EAE model
(i.e., Cup/EAE). As recently demonstrated by our group, cuprizone-induced oligodendrocyte
degeneration triggers peripheral immune cell recruitment into the forebrain [43,44]. Here, we utilized
transgenic (CX3CR1+/eGFP/CCR2+/RFP) mice with eGFP-expressing microglia and RFP-expressing
monocyte-derived macrophages [47] to investigate which cell type expresses TSPO. As shown
in Figure 8J,K, the TSPO signal clearly co-localized to both, eGFP-expressing microglia and
RFP-expressing monocyte-derived macrophages. Although not shown in this study, it has been
reported that TSPO is as well expressed by CD4+ lymphocytes in EAE [72], as it is in humans [73]
and in a model of rheumatoid arthritis [69]. Further studies have to demonstrate to what extent
lymphocytes and other peripheral immune cells contribute to the increased TSPO ligand uptake
observed in MS lesions.
Axonal degeneration is believed to be a major cause of permanent neurological disability in MS
patients. It is assumed that myelinated axons contain two populations of mitochondria: stationary and
motile mitochondria. It has been shown that the volume of mitochondrial stationary sites is increased
in demyelinated CNS axons [53]. In light of these findings, it is of interest to speculate whether some
of the white matter TSPO radioligand uptake observed in PET studies is due to mitochondrial binding
in acutely injured axons. 3D reconstructions of serial block-face scanning electron microscopy images
showed an accumulation of mitochondria within axonal swellings. Furthermore, immunofluorescence
double-labelling experiments revealed accumulations of the mitochondrial protein COXIV at sites of
amyloid precursor protein (APP) accumulation (see Figure 7). The most commonly-used marker to
visualize axonal transport deficits is the APP [74]. APP is an integral glycoprotein type 1, which is
transported towards the axon terminal via anterograde axonal transport [75]. In case of a disturbed
axonal transport machinery, APP accumulates at the side of axon injury and can then be visualized by
immunohistochemistry as so called “spheroids” [76,77]. Although we found a clear co-localization
of COXIV and APP, such a co-localization was not found for TSPO and APP. As already stated
above, there is growing realization that axonal degeneration plays a pivotal role in the development
of neurological disability in patients with MS. In histopathological studies, acute axonal injury,
as defined by the accumulation of APP, was found to occur not only in active demyelinating but
also in remyelinating and inactive demyelinated MS lesions [78,79]. Although it is currently not clear
why mitochondria do not express TSPO within injured axons, diffuse axonal degeneration probably
does not contribute to TSPO-ligand uptake in MS tissues.
PET ligands targeting TSPO represent promising tools to visualize neuroinflammation in MS
patients. This may provide information beyond contrast-enhanced MRI and is readily applicable to all
patients. This study illustrates that the pathological substrate of an increase in TSPO ligand binding
might be diverse including microglia activation, peripheral monocyte recruitment, and astrocytosis.
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